MabDesign’s market analyses give you a monthly overview of market dynamics and projects in development for a given indication or technology, to help you better understand the constantly evolving market of biologics and biomanufacturing. This month, we take a look at the melanoma market, and the biomedicines in development targeting this pathology.
Skin cancers are the most frequently diagnosed cancers worldwide. In 2022, melanoma accounted for 330,000 new cases diagnosed worldwide, and almost 60,000 deaths.
Standard treatment options for melanoma include surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy. Nine biomedicines are currently on the market in this indication: one vaccine, one cell therapy, and 7 Immune Check point Inhibitors (excluding biosimilars and combination therapies. The use of checkpoint inhibitors has improved clinical outcomes.
In the development pipeline, monoclonal antibodies represent the majority of products (38%). Nevertheless, many other approaches are also in development, with a varied pipeline of 736 unique products.
biomedicines in development targeting a melanoma indication by molecule type
Pipeline and the melanoma market
Deals & Recent clinical successes
Immunotherapies based on tumor-infiltrating lymphocytes (TILs) and CAR-T cells are an attractive treatment option, as they are capable of boosting the immune response. Lifileucel, a TIL therapy, was recently approved by the FDA for the treatment of advanced melanoma. Other therapeutic options are under investigation, such as those based on the microbiome.
Want to find out more?
To find out more, register for the MabDesign Academy “Biotherapies in Oncology” on June 19, 2024 in Montpellier! The course will focus on the therapeutic arsenal for treating cancers, immuno-oncology and ADCs .
MabDesign has acquired and cultivates its expertise in all market segments associated with biopharmaceuticals and biomanufacturing. Our team of consultants is at your disposal to support you in all your biotherapy-related projects. Feel free to explore our range of services, including our marketing and strategic analyses, if you’d like to find out more!
Sources: MabDesign, Globocan & GlobalData
Date – April 2024
